Scroll

vorinostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histone deacetylase inhibitors	4124	149647-78-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vorinostat suberoylanilide hydroxamic acid	A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. Molecular weight: 264.33 Formula: C14H20N2O3 CLOGP: 0.99 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 78.43 ALOGS: -3.57 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vorinostat
suberoylanilide hydroxamic acid

A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.

Molecular weight: 264.33
Formula: C14H20N2O3
CLOGP: 0.99
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 78.43
ALOGS: -3.57
ROTB: 8

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	43 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	28 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
t_half (Half-life)	0.76 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.50 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.29 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.07 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Oct. 6, 2006	FDA	MERCK

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	177.27	40.78	73	1275	118376	63369298
Electrocardiogram QT prolonged	79.60	40.78	34	1314	59496	63428178
Dehydration	57.21	40.78	39	1309	173315	63314359
Thrombocytopenia	47.45	40.78	33	1315	151124	63336550
Product use in unapproved indication	46.86	40.78	35	1313	179045	63308629
Platelet count decreased	42.74	40.78	28	1320	116094	63371580
Cutaneous T-cell lymphoma	42.61	40.78	9	1339	1371	63486303
Sepsis	42.44	40.78	31	1317	153092	63334582

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Torsade de pointes	79.38	32.83	24	1577	7185	34948145
Lymphopenia	60.16	32.83	24	1577	16311	34939019
Febrile neutropenia	52.46	32.83	46	1555	136803	34818527
Product use in unapproved indication	46.00	32.83	40	1561	117459	34837871
Anaemia	36.77	32.83	49	1552	233286	34722044
Electrocardiogram abnormal	35.46	32.83	14	1587	9233	34946097
Platelet count decreased	33.78	32.83	34	1567	119683	34835647

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	145.79	29.20	94	2705	230905	79510684
Product use in unapproved indication	127.01	29.20	89	2710	250270	79491319
Torsade de pointes	77.00	29.20	28	2771	19284	79722305
Platelet count decreased	69.07	29.20	56	2743	194608	79546981
Cutaneous T-cell lymphoma	56.05	29.20	14	2785	2689	79738900
Thrombocytopenia	56.00	29.20	57	2742	265202	79476387
Product administered to patient of inappropriate age	50.38	29.20	15	2784	5538	79736051
Sepsis	44.71	29.20	51	2748	269377	79472212
Malignant neoplasm progression	43.73	29.20	37	2762	135953	79605636
Acute myeloid leukaemia	42.40	29.20	21	2778	30864	79710725

Showing 1 to 10 of 16 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01XH01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Histone deacetylase (HDAC) inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:61115	histone deacetylase inhibitors
CHEBI has role	CHEBI:68495	Type I cell-death inducers
FDA EPC	N0000175588	Histone Deacetylase Inhibitor
FDA MoA	N0000175071	Histone Deacetylase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D056572	Histone Deacetylase Inhibitors

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Primary cutaneous T-cell lymphoma	indication	400122007
Hypocalcemia	contraindication	5291005
Dehydration	contraindication	34095006
Hypokalemia	contraindication	43339004
Diarrhea	contraindication	62315008
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Prolonged QT interval	contraindication	111975006
Deep venous thrombosis	contraindication	128053003
Hypomagnesemia	contraindication	190855004

Showing 1 to 10 of 19 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.34	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	7732490	March 4, 2023	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	8067472	March 4, 2023	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	8101663	March 4, 2023	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	7851509	Feb. 21, 2024	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	7399787	Feb. 9, 2025	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
100MG	ZOLINZA	MSD SUB MERCK	N021991	Oct. 6, 2006	RX	CAPSULE	ORAL	8450372	March 18, 2028	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Showing 1 to 6 of 6 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histone deacetylase 2	Enzyme	Q92769	HDAC2_HUMAN	INHIBITOR	Ki	8.80	CHEMBL	CHEMBL
Histone deacetylase 1	Enzyme	Q13547	HDAC1_HUMAN	INHIBITOR	Ki	8.89	CHEMBL	CHEMBL
Histone deacetylase 3	Enzyme	O15379	HDAC3_HUMAN	INHIBITOR	Ki	8.30	CHEMBL	CHEMBL
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN	INHIBITOR	Ki	9	CHEMBL	CHEMBL
Histone deacetylase 8	Enzyme	Q9BY41	HDAC8_HUMAN		Ki	6.76	CHEMBL
Histone deacetylase 4	Enzyme	P56524	HDAC4_HUMAN		Ki	7.80	CHEMBL
Histone deacetylase 9	Enzyme	Q9UKV0	HDAC9_HUMAN		Ki	7.31	CHEMBL
Leukotriene A-4 hydrolase	Enzyme	P09960	LKHA4_HUMAN		IC50	5.12	CHEMBL
Histone deacetylase 10	Enzyme	Q969S8	HDA10_HUMAN		Ki	7.30	CHEMBL
Histone deacetylase 11	Enzyme	Q96DB2	HDA11_HUMAN		Ki	7.89	CHEMBL

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
011760	NDDF
194337	RXNORM
22259	MMSL
4025777	VUID
4025777	VANDF
422505001	SNOMEDCT_US
422523009	SNOMEDCT_US
5311	PUBCHEM_CID
58IFB293JI	UNII
6852	IUPHAR_LIGAND_ID

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZOLINZA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0568	CAPSULE	100 mg	ORAL	NDA	30 sections
ZOLINZA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0568	CAPSULE	100 mg	ORAL	NDA	30 sections

Showing 1 to 2 of 2 entries

Previous1Next